Michael Marinaro Biography and Net Worth

EVP of Medtronic

Mike is a seasoned leader with more than 20 years of experience leading numerous organizations across Medtronic. Mike began his Medtronic career in the field, representing and then leading U.S. Coronary, Peripheral, and broader Cardiovascular Group sales teams in Cardiac rhythm therapies before becoming a general manager.

Mike oversees a comprehensive, market-leading surgical portfolio of products as the recently appointed Executive Vice President and President of the newly combined Surgical Operating Unit; bringing together a legacy of surgical devices and the new robotic-assisted surgery technology to redefine the future of surgery. Most recently, Mike oversaw the Surgical Robotics business where he readied the organization for growth and scale to bring the benefits of robotic-assisted surgery through the recently commercially available Hugo™ RAS system with Touch Surgery™ Enterprise to patients around the world.

Previously, Mike also led the Tachycardia, Bradycardia, and Infection Control teams where he spearheaded initiatives to bring implantable products to market — from innovation through launch to market success. Mike spent four years as president of the Cardiac Rhythm Management Operating Unit. In this role, he led the adoption of the Micra™ transcatheter pacing system, the TYRX™ franchise, and the company’s successful expansion of its business in China.

A leader who is passionate about empowering teams and individuals to achieve their full potential, Mike has been recognized with numerous awards at Medtronic, including the President's Club, Star of Excellence, and Wallin Leadership programs. In 2018, he received a Medtronic Global Inclusion, Diversity, and Engagement (GIDE) award, recognizing his efforts to actively champion strong employee engagement programs, an inclusive work environment, and contributions from different perspectives.

Mike held roles at pharmaceutical and medical device companies prior to joining Medtronic in 2000. He received his bachelor’s degree from Boston College.

What is Michael Marinaro's net worth?

The estimated net worth of Michael Marinaro is at least $2.22 million as of April 8th, 2024. Mr. Marinaro owns 27,925 shares of Medtronic stock worth more than $2,219,479 as of July 21st. This net worth approximation does not reflect any other assets that Mr. Marinaro may own. Learn More about Michael Marinaro's net worth.

How do I contact Michael Marinaro?

The corporate mailing address for Mr. Marinaro and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Michael Marinaro's contact information.

Has Michael Marinaro been buying or selling shares of Medtronic?

Michael Marinaro has not been actively trading shares of Medtronic within the last three months. Most recently, Michael Marinaro sold 854 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $83.14, for a transaction totalling $71,001.56. Following the completion of the sale, the executive vice president now directly owns 27,925 shares of the company's stock, valued at $2,321,684.50. Learn More on Michael Marinaro's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 7 times. They sold a total of 68,011 shares worth more than $5,731,263.13. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 6/7/2024.

Michael Marinaro Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2024Sell854$83.14$71,001.5627,925View SEC Filing Icon  
8/4/2023Sell1,352$84.11$113,716.7228,930View SEC Filing Icon  
See Full Table

Michael Marinaro Buying and Selling Activity at Medtronic

This chart shows Michael Marinaro's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $79.48
Low: $79.41
High: $81.67

50 Day Range

MA: $80.93
Low: $76.84
High: $85.92

2 Week Range

Now: $79.48
Low: $68.84
High: $91.00


9,292,752 shs

Average Volume

6,365,736 shs

Market Capitalization

$101.91 billion

P/E Ratio


Dividend Yield